257 related articles for article (PubMed ID: 31493211)
1. Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.
Gao S; Du S; Lu Z; Xin J; Gao S; Sun H
Eur Radiol; 2020 Feb; 30(2):1191-1201. PubMed ID: 31493211
[TBL] [Abstract][Full Text] [Related]
2. Early treatment response of patients undergoing concurrent chemoradiotherapy for cervical cancer: An evaluation of integrated multi-parameter PET-IVIM MR.
Xu C; Sun H; Du S; Xin J
Eur J Radiol; 2019 Aug; 117():1-8. PubMed ID: 31307633
[TBL] [Abstract][Full Text] [Related]
3. Value of integrated PET-IVIM MR in assessing metastases in hypermetabolic pelvic lymph nodes in cervical cancer: a multi-parameter study.
Xu C; Du S; Zhang S; Wang B; Dong C; Sun H
Eur Radiol; 2020 May; 30(5):2483-2492. PubMed ID: 32040728
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
[TBL] [Abstract][Full Text] [Related]
5. Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy.
Vojtíšek R; Baxa J; Kovářová P; Almortaza A; Hošek P; Sukovská E; Tupý R; Ferda J; Fínek J
Strahlenther Onkol; 2021 Jun; 197(6):494-504. PubMed ID: 33492444
[TBL] [Abstract][Full Text] [Related]
6. The role of
Rufini V; Collarino A; Calcagni ML; Meduri GM; Fuoco V; Pasciuto T; Testa AC; Ferrandina G; Gambacorta MA; Campitelli M; Gui B; Zannoni G; Manfredi R; Scambia G; Giordano A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1228-1238. PubMed ID: 31414206
[TBL] [Abstract][Full Text] [Related]
7. Combinative evaluation of primary tumor and lymph nodes to predict pelvic lymphatic metastasis in cervical cancer: an integrated PET-IVIM MRI study.
Xu C; Li X; Shi Y; Wang B; Sun H
Cancer Imaging; 2020 Mar; 20(1):21. PubMed ID: 32143736
[TBL] [Abstract][Full Text] [Related]
8. Relationship between
Du S; Sun H; Gao S; Xin J; Lu Z; Chen Z; Pan S; Guo Q
Clin Radiol; 2019 Mar; 74(3):178-186. PubMed ID: 30545566
[TBL] [Abstract][Full Text] [Related]
9. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer.
Leseur J; Roman-Jimenez G; Devillers A; Ospina-Arango JD; Williaume D; Castelli J; Terve P; Lavoue V; Garin E; Lejeune F; Acosta O; De Crevoisier R
Radiother Oncol; 2016 Sep; 120(3):512-518. PubMed ID: 27569847
[TBL] [Abstract][Full Text] [Related]
10. Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer.
Ueno Y; Lisbona R; Tamada T; Alaref A; Sugimura K; Reinhold C
Br J Radiol; 2017 Jul; 90(1075):20170035. PubMed ID: 28508679
[TBL] [Abstract][Full Text] [Related]
11. Value of integrated PET-IVIM MRI in predicting lymphovascular space invasion in cervical cancer without lymphatic metastasis.
Xu C; Yu Y; Li X; Sun H
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2990-3000. PubMed ID: 33506309
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment prediction of early response to chemoradiotherapy by quantitative analysis of baseline staging FDG-PET/CT and MRI in locally advanced cervical cancer.
Min LA; Ackermans LL; Nowee ME; Griethuysen JJV; Roberti S; Maas M; Vogel WV; Beets-Tan RG; Lambregts DM
Acta Radiol; 2021 Jul; 62(7):940-948. PubMed ID: 32722967
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
Voglimacci M; Gabiache E; Lusque A; Ferron G; Ducassou A; Querleu D; Motton S; Chantalat E; Courbon F; Martinez A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1551-1559. PubMed ID: 30729273
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy.
Chong GO; Jeong SY; Park SH; Lee YH; Lee SW; Hong DG; Kim JC; Lee YS; Cho YL
PLoS One; 2015; 10(9):e0137743. PubMed ID: 26368542
[TBL] [Abstract][Full Text] [Related]
15. Combinative evaluation of primary tumor and lymph nodes in predicting pelvic lymphatic metastasis in early-stage cervical cancer: A multiparametric PET-CT study.
Li K; Sun H; Guo Q
Eur J Radiol; 2019 Apr; 113():153-157. PubMed ID: 30927941
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of posttreatment
Lima GM; Matti A; Vara G; Dondi G; Naselli N; De Crescenzo EM; Morganti AG; Perrone AM; De Iaco P; Nanni C; Fanti S
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2139-2146. PubMed ID: 30069578
[TBL] [Abstract][Full Text] [Related]
17. Metabolic parameters with different thresholds for evaluating tumor recurrence and their correlations with hematological parameters in locally advanced squamous cell cervical carcinoma: an observational
Du S; Sun H; Gao S; Xin J; Lu Z
Quant Imaging Med Surg; 2019 Mar; 9(3):440-452. PubMed ID: 31032191
[TBL] [Abstract][Full Text] [Related]
18. Prediction of outcome using pretreatment
Lucia F; Visvikis D; Desseroit MC; Miranda O; Malhaire JP; Robin P; Pradier O; Hatt M; Schick U
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):768-786. PubMed ID: 29222685
[TBL] [Abstract][Full Text] [Related]
19. Prediction of local relapse and distant metastasis in patients with definitive chemoradiotherapy-treated cervical cancer by deep learning from [
Shen WC; Chen SW; Wu KC; Hsieh TC; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yen KY; Kao CH
Eur Radiol; 2019 Dec; 29(12):6741-6749. PubMed ID: 31134366
[TBL] [Abstract][Full Text] [Related]
20. Metabolic activity determines survival depending on the level of lymph node involvement in cervical cancer.
Martinez A; Chantalat E; Angeles MA; Ferron G; Ducassou A; Daix M; Attal J; Bétrian S; Lusque A; Gabiache E
BMC Cancer; 2022 Jul; 22(1):810. PubMed ID: 35870900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
